Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: Results from the ESTHER trial

Annals of the Rheumatic Diseases

Volumn 72, Issue 6, 2013, Pages 823-825

  Song, In Ho ^a   Weiß, Anja ^b   Hermann, Kay Geert A ^a   Haibel, Hildrun ^a   Althoff, Christian E ^a   Poddubnyy, Denis ^a   Listing, Joachim ^b   Lange, Ekkehard ^c   Freundlich, Bruce ^d   Rudwaleit, Martin ^a,e   Sieper, Joachim ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b German Rheumatism Research Center   (Germany)

^c PFIZER INC   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e Endokrinologikum   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; ETANERCEPT; HLA B27 ANTIGEN; SALAZOSULFAPYRIDINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BATH ANKYLOSING SPONDYLITIS DISEASE ACTIVITY INDEX; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SACROILIAC JOINT; SPONDYLARTHRITIS; TREATMENT DURATION;

ANKYLOSING SPONDYLITIS; ANTI-TNF; MAGNETIC RESONANCE IMAGING; SPONDYLOARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MAGNETIC RESONANCE IMAGING; MALE; RECEPTORS, TUMOR NECROSIS FACTOR; SACROILIAC JOINT; SPINE; SPONDYLARTHRITIS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84877615681     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202389     Document Type: Article

References (18)

1. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8. (Pubitemid 14134775)
2. Rudwaleit M, van der Heijde D, Landewe R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
3. Rudwaleit M, Haibel H, Baraliakos X, et al. The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort. Arthritis Rheum 2009;60:717-27.
4. Kiltz U, Baraliakos X, Karakostas P, et al. Patients with non-radiographic axial spondyloarthritis differ from patients with ankylosing spondylitis in several aspects. Arthritis Care Res (Hoboken) 2012;64:1415-22.
5. Song IH, Hermann K, Haibel H, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011;70:590-6.
6. Haibel H, Rudwaleit M, Listing J, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a 12-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008;58:1981-91. (Pubitemid 351988090)
7. Barkham N, Keen HI, Coates LC, et al . Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009;60:946-54.
8. Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. Ann Rheum Dis 2004;63:1438-44. (Pubitemid 39433948)
9. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86. (Pubitemid 32758236)
10. Machado P, Landewe R, Lie E, et al . Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011;70:47-53.
11. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009;68(Suppl 2):ii1-44.
12. Mager AK, Althoff CE, Sieper J, et al. Role of whole-body magnetic resonance imaging in diagnosing early spondyloarthritis. Eur J Radiol 2009;71:182-8.
13. Althoff CE, Appel H, Rudwaleit M, et al. Whole-body MRI as a new screening tool for detecting axial and peripheral manifestations of spondyloarthritis. Ann Rheum Dis 2007;66:983-5. (Pubitemid 46999809)
14. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009;36:801-8.
15. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004;63:665-70. (Pubitemid 38658395)
16. Sieper J, van der Heijde D, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2012. Published Online First 7 Jul 2012.
17. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005;52:582-91. (Pubitemid 40216323)
18. van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006;54:2136-46. (Pubitemid 44051069)